Recent Advances in and Applications of Ex Vivo Drug Sensitivity Analysis for Blood Cancers

Overview

Journal Blood Res

Publisher Springer Nature

Specialty Hematology

Date 2024 Nov 6

PMID 39503808

Authors

Haeryung Lee

Nahee Ko

Sujin Namgoong

Seunghyok Ham

Jamin Koo

Affiliations

Soon will be listed here.

Abstract

Blood cancers, including leukemia, multiple myeloma, and lymphoma, pose significant challenges owing to their heterogeneous nature and the limitations of traditional treatments. Precision medicine has emerged as a transformative approach that offers tailored therapeutic strategies based on individual patient profiles. Ex vivo drug sensitivity analysis is central to this advancement, which enables testing of patient-derived cancer cells against a panel of therapeutic agents to predict clinical responses. This review provides a comprehensive overview of the latest advancements in ex vivo drug sensitivity analyses and their application in blood cancers. We discuss the development of more comprehensive drug response metrics and the evaluation of drug combinations to identify synergistic interactions. Additionally, we present evaluation of the advanced therapeutics such as antibody-drug conjugates using ex vivo assays. This review describes the critical role of ex vivo drug sensitivity analyses in advancing precision medicine by examining technological innovations and clinical applications. Ultimately, these innovations are paving the way for more effective and individualized treatments, improving patient outcomes, and establishing new standards for the management of blood cancers.

References

Kropivsek K, Kachel P, Goetze S, Wegmann R, Festl Y, Severin Y . Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. Nat Cancer. 2023; 4(5):734-753. PMC: 10212768. DOI: 10.1038/s43018-023-00544-9. View

Greenbaum A, Fromm J, Gopal A, Houghton A . Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8 T-cells despite immune checkpoint signaling. Blood Res. 2022; 57(2):117-128. PMC: 9242835. DOI: 10.5045/br.2022.2021145. View

Park S, Lee J, Byun J, Choi G, Kim K, Lim S . ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma. NPJ Precis Oncol. 2023; 7(1):46. PMC: 10199943. DOI: 10.1038/s41698-023-00385-w. View

Zinshteyn B, Chan D, England W, Feng C, Green R, Spitale R . Assaying RNA structure with LASER-Seq. Nucleic Acids Res. 2018; 47(1):43-55. PMC: 6326810. DOI: 10.1093/nar/gky1172. View

Shin S, Bode A, Dong Z . Precision medicine: the foundation of future cancer therapeutics. NPJ Precis Oncol. 2018; 1(1):12. PMC: 5871793. DOI: 10.1038/s41698-017-0016-z. View

Kim S, Jung S, Yhim H, Jo J, Song G, Kim M . Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. Blood Res. 2022; 57(1):51-58. PMC: 8958375. DOI: 10.5045/br.2021.2021176. View

Ahn J, Kim H . mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022; 57(S1):32-36. PMC: 9057665. DOI: 10.5045/br.2022.2022017. View

Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K . A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020; 4(5):906-919. PMC: 7065489. DOI: 10.1182/bloodadvances.2019001188. View

Andersson E, Putzer S, Yadav B, Dufva O, Khan S, He L . Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2017; 32(3):774-787. DOI: 10.1038/leu.2017.252. View

10.

Chen D, Wang X, Zhu H, Jiang Y, Li Y, Liu Q . Predicting anticancer synergistic drug combinations based on multi-task learning. BMC Bioinformatics. 2023; 24(1):448. PMC: 10680313. DOI: 10.1186/s12859-023-05524-5. View

11.

Maiti A, Konopleva M . How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia. Cancer J. 2022; 28(1):2-13. PMC: 8785772. DOI: 10.1097/PPO.0000000000000567. View

12.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M . A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia. 2009; 23(8):1389-97. DOI: 10.1038/leu.2009.34. View

13.

De Mel S, Rashid M, Zhang X, Goh J, Lee C, Poon L . Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. Blood Cancer J. 2020; 10(1):9. PMC: 6985240. DOI: 10.1038/s41408-020-0276-7. View

14.

Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J . Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2019; 135(9):597-609. PMC: 7098811. DOI: 10.1182/blood.2019002121. View

15.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T . Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013; 12(10):2031-42. DOI: 10.1158/1535-7163.MCT-12-1182. View

16.

Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C . Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123. Nat Biotechnol. 2023; 41(9):1296-1306. PMC: 10497414. DOI: 10.1038/s41587-022-01626-2. View

17.

Makela P, Zhang S, Rudd S . Drug synergy scoring using minimal dose response matrices. BMC Res Notes. 2021; 14(1):27. PMC: 7816329. DOI: 10.1186/s13104-021-05445-7. View

18.

Hamann P, Hinman L, Hollander I, Beyer C, Lindh D, Holcomb R . Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002; 13(1):47-58. DOI: 10.1021/bc010021y. View

19.

Yang C, Lu P, Lee F, Chadburn A, Barrientos J, Leonard J . Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia. 2008; 22(9):1755-66. DOI: 10.1038/leu.2008.163. View

20.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle P, Kufer P . Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. Curr Clin Pharmacol. 2018; 13(1):55-64. PMC: 6327122. DOI: 10.2174/1574884713666180518102514. View